tag novartis 
MedCity News
JULY 1, 2022
Novartis is acquiring an FDA priority review voucher from Mallinckrodt Pharmaceuticals. The $100 million price tag is in the neighborhood of the going rate for these vouchers, which grant a company a shorter regulatory review timeline for a drug that addresses a rare or neglected disease.
pharmaphorum
JANUARY 9, 2023
Novartis’ programme providing free access to its spinal muscular atrophy (SMA) gene therapy Zolgensma is being scaled back to a dozen countries worldwide, according to the company. That comes to an end today however, as Novartis is winnowing down the countries where the gMAP pathway will be available. Pause in UK access.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
SEPTEMBER 30, 2022
Spark Therapeutics’ Luxturna, indicated for inherited retinal disease (IRD), was the first gene therapy to be approved, in 2017, with a price tag of $850,000 for each eye. bluebird then broke its own pricing record when the $3m Skysona was approved, and now faces the unique challenge of selling the world's two most expensive drugs.
pharmaphorum
DECEMBER 23, 2022
Add to this the considerable cost of these medications – the first approved CAR-T, Novartis’ Kymriah (tisagenlecleucel), had a U.S. price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting.
Pharmaceutical Technology
MAY 15, 2023
Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.
European Pharmaceutical Review
MAY 11, 2023
Novartis shared long-term data for its SMA gene therapy in March 2023, which indicated significant long-term motor-milestone achievements in spinal muscular atrophy (SMA). 1 This is assuming a $1M price tag for all gene therapies. She has led Clinical Development for Novartis Gene Therapies since 2020.
pharmaphorum
NOVEMBER 16, 2022
However, with a price tag of €1.58 The body has often gone against industry pricing models, notably in the case of Novartis’ Zolgensma (onasemnogene abeparvovec), which was previously the most expensive treatment in the world. How to navigate the new climate. At more than $2.1 At more than $2.1
Expert insights. Personalized for you.
106 
Let's personalize your content